Opinion|Videos|January 13, 2025
Looking Ahead: Ph+ ALL in 2025 and Beyond
Dr. Bijal Shah offers forward-looking perspectives on the future of Ph+ ALL treatment, highlighting potential advancements, emerging challenges, and opportunities for improving patient care in 2025 and beyond.
Advertisement
- Closing thoughts
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
5